Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Ketorolac; Ketorolac Tromethamine; Lubricant Eye Drops; Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Patients scheduled to undergo phakic IOL implantation

Exclusion Criteria:

• History of intraocular surgery in the operative eye